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ABSTRACT
BACKGROUNDANDPURPOSE: AlthoughDiffeomorphic Anatomical Registration Through Exponentiated Lie Algebra (DARTEL) has been
introduced as an alternative to conventional voxel-based morphometry, there are scant data available regarding the optimal image-
processing settings. The aim of this study was to optimize image-processing and ROI settings for the diagnosis of Alzheimer disease using
DARTEL.
MATERIALS ANDMETHODS: BetweenMay 2002 and August 2014, we selected 158 patients with Alzheimer disease and 198 age-matched
healthy subjects; 158 healthy subjects served as the control group against the patients with Alzheimer disease, and the remaining 40 served
as the healthy data base. Structural MR images were obtained in all the participants and were processed using DARTEL-based voxel-based
morphometrywith a variety of settings. These includedmodulated or nonmodulated, nonsmoothedor smoothed settingswith a 4-, 8-, 12-,
16-, or 20-mmkernel size. A z scorewas calculated for each ROI, and univariate andmultivariate logistic regression analyseswere performed
to determine the optimal ROI settings for each dataset. The optimal settings were deﬁned as those demonstrating the highest 2 test
statistics in the multivariate logistic regression analyses. Finally, using the optimal settings, we obtained receiver operating characteristic
curves. The models were veriﬁed using 10-fold cross-validation.
RESULTS: The optimal settings were obtained using the hippocampus and precuneus as ROIs without modulation and smoothing. The
average area under the curve was 0.845 (95% conﬁdence interval, 0.788–0.902).
CONCLUSIONS: We recommend using the precuneus and hippocampus as ROIs without modulation and smoothing for DARTEL-based
voxel-based morphometry as a tool for diagnosing Alzheimer disease.
ABBREVIATIONS: AD  Alzheimer disease; AUC  area under the curve; CDR  Clinical Dementia Rating; DARTEL  Diffeomorphic Anatomical Registration
Through Exponentiated Lie Algebra; HS  healthy subjects; MMSE  Mini-Mental State Examination; ROC  receiver operating characteristic; VBM  voxel-based
morphometry
Statistical neuroimaging analysis techniques such as voxel-basedmorphometry (VBM)have beenwidely used to evaluate
structural MR imaging data, but in recent years, such methods
have been suggested as a diagnostic aid for the early detection of
Alzheimer disease (AD).1,2 However, conventional VBM has of-
ten been criticized due to its imperfect registration of individual
images of the standard brain.3 Diffeomorphic Anatomical Regis-
tration Through Exponentiated Lie Algebra (DARTEL) has been
introduced as an alternative method to conventional VBM due to
novel abilities allowing precise segmentation and normalization
of images.4 Some studies have reported thatDARTEL-basedVBM
provides a greater diagnostic accuracy for the detection of AD
than conventional VBM methods.5 Modulation, which involves
the scaling of images depending on the extent of expansion or
contraction, is considered an important processing step for
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DARTEL-based VBM. The smoothing before statistical image
analysis is also an important factor that can affect VBM results.
However, there are scant data available regarding the optimal im-
age-processing settings for DARTEL-based VBM.
Shima et al6 previously demonstrated that a subset of patients
with AD demonstrate atrophy in neocortical areas such as the
posterior cingulate gyri and parietal lobe rather than in traditional
areas such as the hippocampus, which is particularly true in early-
onset AD. Therefore, it would be conceivable to hypothesize that
optimal ROI settings for the detection ofADmight vary according
to age.
The purpose of this study was to optimize image-processing
and ROI settings for the discrimination of patients with AD from
age-matched healthy subjects using DARTEL-based VBM.
MATERIALS AND METHODS
Subjects
This prospective study was performed as a part of the Ishikawa
Brain Imaging Study, which included any research to seek and
develop imaging biomarkers for early and objective assessment of
AD and other forms of neurodegenerative diseases using PET and
MR imaging.7,8 The study protocol was approved by the Medical
and Pharmacological Research Center Foundation ethics com-
mittee, and written informed consent was obtained from all sub-
jects before participation in the study. Of the 594 consecutive
patients who were examined by neurologists and who underwent
MR imaging (3D-T1-weighted, T2-weighted, MR angiography)
at our memory clinic between May 2002 and August 2014, we
selected 240 patients with a clinical diagnosis of probable AD at an
early stage. Of theMR imaging scans, 3D-T1-weighted scans were
used for both screening and analysis, whereas T2-weighted MR
imaging andMR angiography were used for screening. Diagnosis
of AD was based on the criteria of the National Institute of Neu-
rologic andCommunicativeDisorders and Stroke and the Alzhei-
mer’s Disease and Related Disorders Association.9 Forty-three
patients were excluded from the study on the following
grounds: 1) evidence of moderate-to-severe cognitive distur-
bance: grade 2 or more on the Clinical Dementia Rating
(CDR),10 with evidence of severe language, attentional, or be-
havioral disturbances that might complicate neurologic assess-
ment; 2) uncontrolled major systemic disease or other neuro-
logic disorders; and 3) evidence of focal brain lesions
determined by MR imaging. We also excluded 39 patients with
AD older than 80 years of age because it was impossible to find
suitable age-matched healthy controls. Finally, 158 patients
with AD were enrolled for analysis.
Regarding the generation of a control group for the construc-
tion of a healthy data base and for comparison against patients
with AD, healthy subjects (HS) were recruited in response to ad-
vertisements. The following criteria were used to define healthy:
1) no history of brain trauma, psychiatric or neurologic disorders,
or uncontrolled major systemic diseases and no current use of
centrally acting drugs; 2) no abnormalities following general
and neurologic examination; 3) a Mini-Mental State Examina-
tion (MMSE)11 score of 28 and no clinical evidence of de-
mentia; and 4) no evidence of asymptomatic cerebral infarc-
tion or brain vessel abnormalities on MR imaging. From the
criteria, 704 subjects were determined to be HS among the
1369 recruited volunteers. From the 704 subjects, 198 age-
matched subjects were selected; of these, 158 served as the
control group against the patients with AD and the remaining
40 served as the healthy database.
Imaging Procedure
Both patients with AD andHS underwent structural MR imaging
analysis. The structural MR imaging studies were performed us-
ing a 1.5T system (Signa Horizon; GE Healthcare, Milwaukee,
Wisconsin). A 3D volumetric acquisition of a T1-weighted gradi-
ent-echo sequence produced a gapless series of thin transaxial
sections using a magnetization-prepared rapid acquisition of
gradient-echo sequence (TE/TR, 2.0/9.2ms; flip angle, 20°; acqui-
sition matrix, 256 192; number of slices, 124; pixel size, 0.78
1.04; slice thickness, 1.4 mm).
Image Processing
MR imaging data were analyzed with DARTEL-based spatial nor-
malization with SPM8 software (http://www.fil.ion.ucl.ac.uk/
spm/software/spm12).4 MR images from 158 patients with AD
and 198 HS were used to create templates for the DARTEL-based
normalization technique. During spatial normalization, brain re-
gions are expanded or contracted.Modulation involves scaling by
the amount of expansion or contraction, so that the total amount
of graymatter intensity in themodulated graymatter remains the
same as it would be in the original images. Thus, gray matter
intensity on modulated images should represent tissue volume
rather than tissue concentration on nonmodulated images. Dur-
ing processing, both modulated and nonmodulated gray matter
images were obtained for DARTEL-based VBM analysis. Modu-
lated and nonmodulated gray matter images were nonsmoothed
or smoothed, which is an image blurring using a function with a
4-, 8-, 12-, 16-, or 20-mm full width at half maximum Gaussian
kernel, respectively, to investigate the effect of smoothing kernel
size onDARTEL-basedVBM.Twelve image datasets for each sub-
ject were generated.
Tomographic Z Score Mapping
After the preprocessing of MR imaging data, gray matter MR im-
ages were compared with the mean and SD of normal database
gray matter images using a voxel-by-voxel z score analysis with a
software programdeveloped byMatsuda et al12:Z Score ([Con-
trol Mean] [Individual Value]) / (Control SD). This compari-
sonwas performed so that a positive z score valuewould represent
reduced graymatter concentration or volume. These z scoremaps
were displayed by overlay on tomographic sections. In each z
score map, WFU Pick atlas-based ROIs (Department of Radiol-
ogy of Wake Forest University School of Medicine, Winston-Sa-
lem, North Carolina; fmri.wfubmc.edu)13 were drawn on the
amygdala, hippocampus, parahippocampus, posterior cingulate
gyrus, precuneus, frontal lobe, occipital lobe, parietal lobe, and
temporal lobe.
Analysis
For each dataset, we investigated the diagnostic ability of each
technique to discriminate patients with AD from HS. We per-
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formed 10-fold cross-validation to optimize image-processing
and ROI settings and test the diagnostic performance. The sub-
jects were randomly divided into 10 folds, with the same number
of patients with AD andHS in each fold. In each iteration, 9 of the
folds were used for discovery (optimal setting determination) and
the remaining one was used for validation (diagnostic perfor-
mance test). The scheme of 10-fold cross-validation is illustrated
in Fig 1.
On the basis of the z score, the optimal ROIs for the dis-
crimination of AD under each processing condition were de-
termined using univariate and multivariate logistic regression
analyses referring likelihood ratio 2 test statistic. Although
our patients with AD and healthy subjects were matched for
age and number as a whole, they were not individually
matched. Therefore, we used regular logistic regression rather
than the conditional logistic regression to analyze our datasets.
The optimal settings were defined as the settings demonstrat-
ing the highest 2 test statistics in the multivariate logistic re-
gression analyses. Multivariate logistic regression analyses
were performed using a stepwise back-
ward elimination procedure. To assess
the aging effect, age was entered as a
variable for both univariate and mul-
tivariate analysis.
The validation group was used to es-
timate the diagnostic performance of the
optimal setting with receiver operating
characteristic (ROC) analysis. Diagnos-
tic accuracy was assessed by the area un-
der the curve (AUC). Data were ex-
pressed as mean SD. Comparisons of
mean values were performed with
ANOVA. When assumptions required
for the ANOVA were not met, the non-
parametric 2-sided Kruskal-Wallis test
was used. The proportional difference
among the groups was assessed using a
2 test. Statistical significance was de-
fined as P .05 (2-sided). All the statis-
tical analyses were performed using a
statistical software package (JMP 10;
SAS Institute. Cary, North Carolina).
RESULTS
Clinical characteristics of patients with
AD, HS, and the healthy database are
summarized in Table 1. Clinical charac-
teristics of the discovery and valida-
tion groups in the tests 1–10
are shown in On-line Tables 1A–10A.
The results of univariate and multivari-
ate analyses for the discrimination of pa-
tients with AD fromHS in the tests 1–10
are shown in On-line Tables 1B–1G,
2B–2G, 3B–3G, 4B–4G, 5B–5G, 6B–6G,
7B–7G, 8B–8G, 9B–9G, and 10B–10G.
The summaries of the optimal ROIs and
diagnostic performance expressed as
AUCs for each image-processing setting are shown in On-line Ta-
bles 1H–10H. Finally, the summary of 10-fold cross-validation is
shown in Table 2.
Determination of Optimal Image-Processing and ROI
Settings
When the smoothing kernel size was set to 8–20 mm, the
amygdala and parietal lobe ROIs mainly contributed to the dis-
crimination of AD regardless of the use of modulation (On-
line Tables). When images were modulated and the smoothing
kernel size was set to 0–4mm, the amygdala and posterior cingu-
late gyrus ROIs were the main contributor. When images were
nonmodulated and the smoothing kernel size was set to 0–4mm,
the hippocampus and precuneus ROIs were the predominant
contributor (On-line Tables).
The results of multivariate analysis are summarized in Ta-
ble 2. In 8 of 10 tests, the highest 2 statistic was obtained when
images were nonmodulated and nonsmoothed. Furthermore,
FIG 1. The scheme of 10-fold cross-validation. One hundred ﬁfty-eight subjects with AD and 158
HSwere randomly divided into 10 folds, with the same number of subjects with AD andHS in each
fold. In each iteration, 9 of the folds were used for discovery (optimal setting determination) and
1 fold was used for validation (diagnostic performance test).
Table 1: Clinical characteristics of AD group and HS group
AD (n = 158) HS (n = 158) NDB (n = 40) P Value
Age (yr) 69 8 68 8 69 6 .881a
Onset age (yr) 67 8 –
Sex (M/F) 80:78 87:71 20:20 .692b
MMSE 22.7 3.6 29.0 0.7 29.6 0.6 .001a
CDR (0.5/1) 20/138 –
Term of education (yr) 11.7 2.6 12.2 2.9 12.1 2.3 .196c




AJNR Am J Neuroradiol ●:● ● 2018 www.ajnr.org 3
the optimal ROIs for the above settings mostly included the
hippocampus and precuneus. Age did not survive as a variate
to discriminate patients with AD fromHS in any test. Thus, the
optimal settings for the discrimination of patients with AD
from HS were obtained when ROIs were set to the hippocam-
pus and precuneus without modulation and smoothing in 7 of
the 10 tests.
Most interesting, following modulation, the z score of the
amygdala was increased, and conversely, that of the hippocampus
was reduced. Examples are presented in Fig 2.
Diagnostic Performance of DARTEL-Based VBM Using the
Optimal Image-Processing Settings and ROIs
Using the optimal image-processing and ROI settings deter-
mined by multivariate analyses of the training groups, we per-
formed ROC analyses in each test group to assess the diagnos-
tic ability as shown in Table 2. The AUC ranged from 0.738 to
0.945. When only the results of the ROI settings of the hip-
pocampus and precuneus without modulation and smoothing
(tests 2, 3, 4, 7, 8, 9, and 10) were summarized, the average of
the AUC was 0.845 (95% confidence interval, 0.788–0.902).
Additionally, there was a general trend for the ROC results to
get worse along with smaller 2 statistics as the smooth func-
tion kernel size increased, particularly in nonmodulation set-
tings (On-line Tables).
DISCUSSION
The major finding of this study was that the diagnostic ability of
DARTEL-based VBM was highest when MR images were non-
modulated and nonsmoothed with ROIs set to the hippocampus
and precuneus.
Impact of Modulation on the Discrimination of AD in
DARTEL-Based VBM
In the present study, modulation significantly influenced the di-
agnostic performance of DARTEL-based VBM for AD. Following
modulation, volumetric differences in the amygdala became in-
creasingly visible, and conversely, those of the hippocampus be-
came more obscure. In theory, perfect spatial normalization





2 Test Statistic P Value AUCModulation
Smoothing Kernel
Size (mm)
Test 1  Nonsmoothed Hippocampus 111.92 .001 0.830
Test 2  Nonsmoothed Hippocampus 113.55 .001 0.945
Precuneus
Test 3  Nonsmoothed Hippocampus 120.76 .001 0.869
Precuneus
Test 4  Nonsmoothed Hippocampus 126.04 .001 0.756
Precuneus
Test 5  4 Hippocampus 123.10 .001 0.871
Precuneus
Parahippocampus
Test 6  8 Amygdala 118.83 .001 0.738
Frontal lobe
Parietal lobe
Test 7  Nonsmoothed Hippocampus 124.73 .001 0.836
Precuneus
Test 8  Nonsmoothed Hippocampus 119.94 .001 0.871
Precuneus
Test 9  Nonsmoothed Hippocampus 126.26 .001 0.851
Precuneus
Test 10  Nonsmoothed Hippocampus 127.45 .001 0.787
Precuneus
a Likelihood ratio 2 test statistic and P values were determined by multivariate logistic regression analyses. Optimal image-processing condition and ROI and diagnostic
performance are expressed as area under the curve for each validation group.
FIG 2. Two sample cases of z score maps with and without mod-
ulation from patients with AD. Automated voxel-by-voxel z score
analysis was performed by comparison of the relative gray matter
concentration of patients with the mean and SD of HS. Color-
scaled z score maps were displayed by overlaying them on the
spatially normalized transaxial MR imaging. Smoothing was not
applied. The modulated MR image of the patient with AD (67-year-
old man; MMSE score, 19; CDR, 1) showed a high z score in the
amygdala. The ﬁnding became obscure when the MR image was
nonmodulated. Meanwhile, the nonmodulated MR image of an-
other patient with AD (78-year-old man; MMSE score, 21; CDR, 1)
showed a high z score in the hippocampus. The ﬁnding disap-
peared when the MR image was modulated.
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would result in no detectable differences between the individual
gray matter images unless modulated.
The negative effect of modulation on the hippocampus
might suggest that the detected differences between patients
with AD and healthy subjects are likely to reflect imperfect
registration between images rather than true volume differ-
ences. By contrast, the positive effect of modulation on the
amygdala might suggest that spatial normalization was suc-
cessful. These findings indicate that the effects of modulation
influence each brain region differently, likely dependent on the
structural complexity of each area.
Optimal Smoothing Kernel Size for the Discrimination of
AD by DARTEL-Based VBM
In statistical image analysis, smoothing is routinely applied to
reduce noise, normalize the distribution, and compensate for im-
perfect image registration.14 A previous modulated DARTEL-
based VBM study reported that optimal kernel size varied accord-
ing to the group size.15 The present study indicated that optimal
kernel size varied depending on the use of modulation and varia-
tion in the ROI. If we took into account the above settings, the
optimal setting was without smoothing the images. This result
could be due to an increased ability to detect localized abnormal-
ities by not smoothing. However, this anatomic difference be-
tween patients with AD and HS would be lost with smoothing,
resulting in a smaller 2 and AUC, particularly in nonmodulation
settings. Like the modulation effects as aforementioned, the ef-
fects of smoothing could also be region-dependent. Furthermore,
our observation might be related to the specific programs used in
this study during data processing. Therefore, one should interpret
our results with caution, taking these circumstances into account.
Optimal ROI for the Discrimination of VAD by DARTEL-
Based VBM
To determine a suitable ROI for the diagnosis of AD, previous
VBM studies analyzed corresponding areas of graymatter volume
for patients with AD and HS using group comparison analy-
ses.1,2,4,5,16,17 In the present study, we extracted areas of signifi-
cant correlation for the discrimination of AD using multivariate
logistic regression analysis and determined such areas as ROIs. As
a result, in addition to medial temporal structures, the precuneus
was designated as an optimal ROI for the detection of AD. This is
in line with a previous study by Shima et al6 demonstrating that
some patients with AD show atrophy in neocortical areas such as
the posterior cingulate gyrus and precuneus rather than in the
medial temporal structures, particularly in young patients. Thus,
the diagnostic performance of VBM for the discrimination of AD
could be improved by combining the neocortical areas with me-
dial temporal structures as ROIs.
Effects of Age on the Diagnostic Accuracy of AD with
DARTEL-Based VBM
We did not find aging effects on the choice of VBM parameters
when age was included as a predictor to discriminate AD fromHS
in our regression model. This was perhaps because most of our
patients had late-onset AD as reflected by the mean onset age
(67 8 years) and the age range not being wide enough to show
significant effects. This needs to be addressed in further studies
focusing on young patients with AD.
Limitations
There are limitations to the study. First, the diagnosis of probable
AD was made on the basis of clinical examinations and therefore
may differ from that obtained with final pathologic verification, a
limitation present in many such studies. However, it has been
reported that diagnostic accuracy can exceed 90% in an academic
memory disorders clinic setting.18 Second, we investigated the
optimal settings of DARTEL-based VBM to only discriminate be-
tween patients with AD and healthy subjects. Therefore, our data
cannot be applied to other types of dementia. Finally, the data
would be more robust if we could use our optimized model pa-
rameters applied on outside AD datasets such as the Alzheimer’s
Disease Neuroimaging Initiative data (http://adni.loni.usc.edu/).
However, this proposal is beyond the scope of the current study
and should be addressed in future.
CONCLUSIONS
For the discrimination of VAD from HS using DARTEL-based
VBM, we recommend using the precuneus and hippocampus as
ROIs without modulation and smoothing. The use of optimized
ROIs and image-processing settings can provide a high level of
diagnostic accuracy in the discrimination of AD.
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